Page 4 - Saturnv Capital Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Saturnv capital management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Saturnv Capital Management Today - Breaking & Trending Today

Eqis Capital Management Inc. Has $4.04 Million Stake in Invesco S&P 500 Top 50 ETF (NYSEARCA:XLG)

Endurant Capital Management LP bought a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,041 shares of the company’s stock, valued at approximately $411,000. Endurant Capital Management LP owned […] ....

Blackrock Inc , Iteos Therapeutics Inc , Exchange Commission , Jacobs Levy Equity Management Inc , Saturnv Capital Management , Teos Therapeutics Inc , Jpmorgan Chase Co , Vanguard Group Inc , Teos Therapeutics Company Profile , Endurant Capital Management , Teos Therapeutics , Get Rating , Capital Management , Street Corp , Levy Equity Management , Teos Therapeutics Company , Teos Therapeutics Daily ,

Jefferies Financial Group Inc. Acquires Shares of 1,200,000 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Jefferies Financial Group Inc. bought a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,200,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,112,000. Jefferies Financial Group Inc. owned approximately 4.87% of […] ....

Benjaminl Palleiko , Thomas Andrew Crockett , Cantor Fitzgerald , Kalvista Pharmaceuticals Trading Down , Kalvista Pharmaceuticals , News Ratings For Kalvista Pharmaceuticals Daily , Quarter For Kalvista Pharmaceuticals , Kalvista Pharmaceuticals Profile , Kalvista Pharmaceuticals Inc , Vr Adviser , Opaleye Management Inc , Securities Exchange Commission , Connor Clark Lunn Investment Management Ltd , Needham Company , Saturnv Capital Management , Driehaus Capital Management , Jefferies Financial Group Inc , Jefferies Financial Group , Get Rating , Financial Group , Lunn Investment Management , Capital Management , Vista Pharmaceuticals Trading Down , Andrew Crockett , Exchange Commission , Vista Pharmaceuticals ,

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Receives Consensus Rating of "Buy" from Brokerages

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) has been given an average rating of “Buy” by the nine analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. […] ....

Dennisd Kim , Pault Quinlan , Piper Sandler , William Blair , Saturnv Capital Management , Bain Capital Life Sciences Investors , Cymabay Therapeutics Inc , Perceptive Advisors , Franklin Resources Inc , Cymabay Therapeutics , Get Rating , General Counsel Paul , Capital Life Sciences Investors , Bay Therapeutics , Cymabay Therapeutics Daily , Nasdaq Cbay ,

Cytokinetics (NASDAQ:CYTK) Lifted to "Hold" at StockNews.com

StockNews.com upgraded shares of Cytokinetics (NASDAQ:CYTK – Get Rating) from a sell rating to a hold rating in a research note published on Thursday. CYTK has been the subject of a number of other reports. JMP Securities reissued a buy rating and issued a $71.00 price target on shares of Cytokinetics in a report on […] ....

United States , Johnt Henderson , Roberti Blum , Geode Capital Management , Jpmorgan Chase Co , Cytokinetics Inc , Securities Exchange Commission , Great Point Partners , Cantor Fitzgerald , Chilton Capital Management , Saturnv Capital Management , Get Rating , Moderate Buy , Trading Down , Exchange Commission , Director John , Capital Management , Cytokinetics Daily , Nasdaq Cytk , Stocknews Com ,

Opaleye Management Inc. Acquires New Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Opaleye Management Inc. bought a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) in the fourth quarter, Holdings Channel reports. The firm bought 923,200 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,241,000. KalVista Pharmaceuticals makes up 2.2% of Opaleye Management Inc.’s investment portfolio, making the stock its 14th […] ....

Hong Kong , Thomas Andrew Crockett , Connor Clark Lunn Investment Management Ltd , Needham Company , Opaleye Management Inc , Kalvista Pharmaceuticals Inc , Quarter For Kalvista Pharmaceuticals , Saturnv Capital Management , Kalvista Pharmaceuticals Trading Down , Cantor Fitzgerald , Kalvista Pharmaceuticals Company Profile , Holdings Channel , Hong Kong Ltd , Us Bancorp , Securities Exchange Commission , Kalvista Pharmaceuticals , News Ratings For Kalvista Pharmaceuticals Daily , International Biotechnology Trust , Opaleye Management , Get Rating , Vista Pharmaceuticals , Lunn Investment Management , Biotechnology Trust , Kong Ltd , Vista Pharmaceuticals Trading Down , Christopher Yea ,